Monday, 23 December 2024


InnoCare announces approval of Clinical Trial of TYK2 JH2 allosteric Inhibitor ICP-488 in China

28 March 2022 | News

InnoCare discovered ICP-488 internally

Image credit: shutterstock

Image credit: shutterstock

InnoCare Pharma has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, which is the Company's third innovative drug for the treatment of autoimmune diseases to enter the clinical stage.

ICP-488 is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor that, by binding the JH2 domain, blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and inflammatory diseases.

InnoCare discovered ICP-488 internally. As a novel oral TYK2 allosteric inhibitor, ICP-488 will be developed for the treatment of autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).

Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, "There is a large unmet clinical need for the treatment of autoimmune diseases worldwide. InnoCare has built a strong pipeline in autoimmune diseases. With the approval of ICP-488 for clinical trials, InnoCare will further strengthen its autoimmune disease pipeline and provide better treatment options for patients with autoimmune diseases worldwide."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account